Evaluating tocilizumab safety and immunomodulatory effects under ocular HTLV-1 infection in vitro
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112460 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Jing Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Hauptthemen laut MEDLINE: Human T-lymphotropic virus 1, HTLV-I Infections, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Takeda Science Foundation, Japan Society for the Promotion of Science, Japan Science and Technology Agency.
Abstract (Originalsprache)
There is growing interest in evaluating the safety and therapeutic potential of existing treatments such as tocilizumab (TCZ), an IL-6 receptor antagonist used to treat inflammatory diseases. However, there have been reports of increased inflammation in patients with HTLV-1 uveitis after TCZ treatment, and its ocular safety in the HTLV-1 infected state remains unknown. This study focused on assessing the impact of TCZ on HTLV-1-infected ocular cells using an in vitro model in which retinal pigment epithelial cells were cocultured with irradiated HTLV-1-infected T-cell lines. TCZ did not significantly affect cellular viability, inflammatory markers, or HTLV-1 proviral loads at various concentrations (25/50/100 µg/ml), indicating no increased risk of HTLV-1 viral infection and no exacerbation of the inflammatory aspects of HTLV-1 infection in the ocular cells. These promising results support the potential of TCZ as a safe treatment option for HTLV-1-infected patients, particularly those with eye infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
- Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. Electronic address: koju.oph@tmd.ac.jp.
Förderung
- Takeda Science Foundation
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
- Ministry of Health, Labour and Welfare
- Japan Agency for Medical Research and Development
Zitieren
APA
Zhang, J., Kamoi, K., Zong, Y., Yang, M., Zou, Y., & Ohno-Matsui, K. (2024). Evaluating tocilizumab safety and immunomodulatory effects under ocular HTLV-1 infection in vitro. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112460
Vancouver
Zhang J, Kamoi K, Zong Y, Yang M, Zou Y, Ohno-Matsui K. Evaluating tocilizumab safety and immunomodulatory effects under ocular HTLV-1 infection in vitro. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112460
BibTeX
@article{Zhang2024,
author = {Zhang, Jing and Kamoi, Koju and Zong, Yuan and Yang, Mingming and Zou, Yaru and Ohno-Matsui, Kyoko},
title = {Evaluating tocilizumab safety and immunomodulatory effects under ocular HTLV-1 infection in vitro},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112460}
}
EUVIMED